OBJECTIVE: This article describes the randomized clinical trial methodology for a population-based study of oncology patients receiving cancer care in a public sector medical center. The primary goal is to test the effectiveness of socioculturally tailored collaborative care intervention in improving depression and quality of life outcomes among low-income ethnic minority patients with major depression and cancer. METHODS: The Patient Health Questionnaire (PHQ-9) depression scale was used to identify patients meeting criteria for major depression (one cardinal depression symptom plus a PHQ-9 score of > or =10). Study-eligible patients were >/=90 days from cancer diagnosis who were receiving acute cancer treatment or follow-up care in oncology clinics. Patients with advanced disease limiting life expectancy to <6 months, acutely suicidal or on antipsychotic medication were excluded. Allowing for attrition due to death or loss to follow-up, the study was powered at the 80% level to detect a 20% difference between study arms in the proportion of patients with >/=50% reduction in PHQ-9 symptoms at 12 months. RESULTS: Of 2330 patients screened, 23.2% met criteria. An 82.4% enrollment rate resulted in 446 primarily women being recruited and randomized to intervention or usual care. CONCLUSION: The study applies methods used in primary care depression trials with adaptations for oncology care clinics and for low-income minority patients.
RCT Entities:
OBJECTIVE: This article describes the randomized clinical trial methodology for a population-based study of oncology patients receiving cancer care in a public sector medical center. The primary goal is to test the effectiveness of socioculturally tailored collaborative care intervention in improving depression and quality of life outcomes among low-income ethnic minority patients with major depression and cancer. METHODS: The Patient Health Questionnaire (PHQ-9) depression scale was used to identify patients meeting criteria for major depression (one cardinal depression symptom plus a PHQ-9 score of > or =10). Study-eligible patients were >/=90 days from cancer diagnosis who were receiving acute cancer treatment or follow-up care in oncology clinics. Patients with advanced disease limiting life expectancy to <6 months, acutely suicidal or on antipsychotic medication were excluded. Allowing for attrition due to death or loss to follow-up, the study was powered at the 80% level to detect a 20% difference between study arms in the proportion of patients with >/=50% reduction in PHQ-9 symptoms at 12 months. RESULTS: Of 2330 patients screened, 23.2% met criteria. An 82.4% enrollment rate resulted in 446 primarily women being recruited and randomized to intervention or usual care. CONCLUSION: The study applies methods used in primary care depression trials with adaptations for oncology care clinics and for low-income minority patients.
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Wayne J Katon; Michael Von Korff; Elizabeth H B Lin; Greg Simon; Evette Ludman; Joan Russo; Paul Ciechanowski; Edward Walker; Terry Bush Journal: Arch Gen Psychiatry Date: 2004-10
Authors: Kathleen Ell; Bin Xie; Brenda Quon; David I Quinn; Megan Dwight-Johnson; Pey-Jiuan Lee Journal: J Clin Oncol Date: 2008-09-20 Impact factor: 44.544
Authors: Maria E Garcia; Lisa Ochoa-Frongia; Nathalie Moise; Adrian Aguilera; Alicia Fernandez Journal: J Gen Intern Med Date: 2017-12-18 Impact factor: 5.128